11 citations
,
February 2022 in “JAAD case reports” Abrocitinib, a JAK inhibitor, may help treat atopic dermatitis and alopecia universalis together.
16 citations
,
April 1978 in “Genetics Research” Mice with the ab gene have abnormal sebaceous gland development, affecting sebum production.
September 2024 in “Journal of the American Academy of Dermatology” Baricitinib 4 mg is effective and safe for treating severe alopecia areata.
June 2024 in “British Journal of Dermatology” Alopecia areata greatly affects quality of life, especially mental health, and newer assessment tools better capture this impact than older ones.
4 citations
,
May 2023 in “arXiv (Cornell University)” Current automatic metrics for long-form question answering don't align with human preferences; a multi-faceted evaluation approach is needed.
The Breast Utility Instrument was developed to assess quality of life in breast cancer patients.
April 2017 in “The journal of investigative dermatology/Journal of investigative dermatology” QMSI is a valuable method for studying drug penetration in skin tissues.
31 citations
,
July 2012 in “Journal of Lipid Research” ACBP is crucial for healthy skin in mice.
Current methods can't accurately predict which long-form answers people prefer; evaluations should consider different answer qualities separately.
14 citations
,
June 2022 in “British Journal of Dermatology” A SALT score of ≤ 20 indicates meaningful improvement in alopecia areata treatment.
Baricitinib effectively treats alopecia areata, with over half of patients improving after 52 weeks.
6 citations
,
March 2022 in “IET Image Processing” Targeting the narrowest part of the anterior chamber angle may help prevent pupil block in glaucoma.
25 citations
,
November 2022 in “British journal of dermatology/British journal of dermatology, Supplement” Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.
1 citations
,
April 2017 in “Journal of Investigative Dermatology” Abatacept may help some people with alopecia areata regrow hair.
37 citations
,
January 2015 in “Evidence-based Complementary and Alternative Medicine” An extract from Quercus acutissima bark was found to reduce sebum production and block an enzyme linked to acne.
September 2017 in “Journal of Investigative Dermatology” QMSI effectively maps and quantifies drug distribution in skin tissues.
32 citations
,
January 2017 in “Patient Preference and Adherence” Alopecia affects patients' quality of life, with younger patients and longer-lasting hair loss experiencing greater impact.
July 2024 in “Journal of Investigative Dermatology” Squaric acid dibutylester helps hair growth by increasing certain immune cells in the skin.
December 2022 in “Research Square (Research Square)” The QuantAnts machines can find cancer markers and create CRISPR targets for them.
30 citations
,
August 2021 in “Journal of Ethnopharmacology” Akebia quinata and Akebia trifoliata have many health benefits and potential medical uses.
October 2025 in “Plastic & Reconstructive Surgery” MNC-QQ cell therapy improved hair growth and quality of life in men with androgenic alopecia without adverse effects.
21 citations
,
December 2014 in “Clinics in dermatology” Squaric acid dibutylester effectively treats alopecia areata.
June 2024 in “British Journal of Dermatology” DLQI is a reasonable quality-of-life measure for alopecia patients, but more research is needed.
April 2026 in “Pediatric Dermatology” Current tools inadequately measure quality of life in children with alopecia areata, needing better instruments.
1 citations
,
November 2023 in “Journal of neurology” A patient with a nerve disorder died from infection complications after developing insulin resistance from a treatment.
April 2024 in “The Egyptian Journal of Hospital Medicine ” Current treatments for androgenetic alopecia manage symptoms but don't cure it, and it affects social and psychological well-being.
January 2023 in “Figshare” Patients with advanced breast cancer prioritize quality of life, overall survival, and progression-free survival in treatment decisions.
1 citations
,
June 2020 in “Annals of the rheumatic diseases” Most patients successfully switched from the original adalimumab to a biosimilar with few reverting due to reduced effectiveness or side effects.
November 2023 in “JEADV Clinical Practice” Patients with severe alopecia areata felt better and less anxious or depressed when treated with baricitinib compared to placebo.
3 citations
,
September 2022 in “Journal of the American Academy of Dermatology” Baricitinib is effective and safe for severe alopecia areata, working similarly with or without an atopic background.